Abstract PS6-58: The impact of baseline modified glasgow prognostic score (mGPS) on survival outcomes in in indigenous and non-indigenous patients with advanced breast cancer patients of Western Australia

Abstract

Abstract Introduction: The modified Glasgow prognostic score (mGPS) is known to be useful in prognostication of multiple cancers. The mGPS, which integrates albumin and C-reactive protein, could assist as a possible prognostic marker in breast cancer. Indigenous women have inferior breast cancer survival to non-Indigenous women and may also have a differing inflammatory environment. Here, we examine the utility and impact of baseline mGPS on survival outcomes in women with metastatic breast cancer by Indigenous status. Methods: We retrospectively collected data from the Western Australian Cancer Registry and electronic records for patients diagnosed with breast cancer between 2001 and 2016 with confirmed metastatic disease. Overall survival (OS) were measured from the date of diagnosis until death. mGPS comprised scores of one point given for CRP > 10 mg/L and/or albumin < 3.5 g/dL, therefore having a value of 0 to 2. Results: Of 152 patients with metastatic breast cancer, 89 patients had all relevant data available and were included with a median follow up of 120 months. The median age was 55.3 years. Baseline mGPS was 0 in 46.6 %, 1 in 34.8 % and 2 in 18.6 %. Median OS across Indigenous and non-Indigenous patients combined was significantly worse moving from the mGPS-0 group through mGPS-1 to mGPS 2, 50.0 v 30.0 v 8.0 months respectively (p<0.0001). Looking at the groups separately, both cohorts separately demonstrated inferior median OS in mGPS-2 compared to mGPS-1 patients, 9 v 32 months (p=0.02) for Indigenous patients, and 2.0 vs 25.0 months for non_Indigenous patients (p=0.001). The correlation between mGPS and the neutrophil-to-lymphocyte ratio (NLR) was weak with a Pearson correlation R-value of 0.184 (p=0.085) Conclusion: The study shows that the mGPS is an independent prognostic factor in advanced-stage disease. A higher baseline mGPS score was associated with worse survival in Indigenous and non-Indigenous patients. A larger prospective study is needed to validate the results, inclusive of assessing links between mGPS and OS in different breast cancer sub-types. Citation Format: Azim Khan, Hilary Martin, Lisa Spalding, Andrew Redfern. The impact of baseline modified glasgow prognostic score (mGPS) on survival outcomes in in indigenous and non-indigenous patients with advanced breast cancer patients of Western Australia [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS6-58.